Dyadic International, a Jupiter-based biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, has released financial results for the year ended December 31, 2011. “In 2011, Dyadic made substantial progress across all areas of its business in continuing to lay a foundation for long-term growth through the consummation of opportunities in a diverse group of markets. Foremost among these were our first major collaborations with leading companies in the biopharmaceutical and animal nutrition industries to use Dyadic’s versatile and robust C1 technology to express genes for the production of key enzymes and proteins. These and other transactions contributed to the large increase in research and license revenue which resulted from Dyadic’s continuous process of identifying and securing revenue-generating opportunities with major companies in a variety of industries. Our two non-exclusive biofuels licensees also continued to make significant progress in 2011 toward the development and improvement of highly productive cellulase enzymes. These enzymes have been produced by both licensees at commercial scale in preparation for their commercialization of cellulosic ethanol, biochemicals and other products derived from cellulosic sugars which will generate additional payments to Dyadic” said President and Chief Executive Officer, Mark Emalfarb. More at www.dyadic.com/wt/dyad/investors

Leave a Reply

Your email address will not be published. Required fields are marked *